SG11201407440WA - Meningococcus serogroup x conjugate - Google Patents

Meningococcus serogroup x conjugate

Info

Publication number
SG11201407440WA
SG11201407440WA SG11201407440WA SG11201407440WA SG11201407440WA SG 11201407440W A SG11201407440W A SG 11201407440WA SG 11201407440W A SG11201407440W A SG 11201407440WA SG 11201407440W A SG11201407440W A SG 11201407440WA SG 11201407440W A SG11201407440W A SG 11201407440WA
Authority
SG
Singapore
Prior art keywords
conjugate
via
fiorentina
ch
international
Prior art date
Application number
SG11201407440WA
Inventor
Maria Rosaria Romano
Francesca Micoli
Francesco Berti
Roberto Adamo
Paolo Costantino
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261650025P priority Critical
Priority to US201261698677P priority
Priority to US201361799528P priority
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to PCT/EP2013/060447 priority patent/WO2013174832A1/en
Publication of SG11201407440WA publication Critical patent/SG11201407440WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/88Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8827Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/88Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8836Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving saccharides

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 November 2013 (28.11.2013) WIPOIPCT (10) International Publication Number WO 2013/174832 A1 (51) International Patent Classification: A61K 47/48 (2006.01) G01N30/06 (2006.01) A61K39/095 (2006.01) G01N30/96 (2006.01) A61P 31/04 ( 2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/060447 22 May 2013 (22.05.2013) English (30) Priority Data: 61/650,025 22 May 2012 (22.05.2012) 61/698,677 9 September 2012 (09.09.2012) 61/799,528 15 March 2013 (15.03.2013) English US US us (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). (72) Inventors: ROMANO, Maria Rosaria; Novartis Vaccines and Diagnostics SrL, Via Fiorentina 1, 1-53100 Siena (IT). MICOLI, Francesca; Novartis Vaccines Institute for Global Health, Via Fiorentina 1, 1-53100 Siena (IT). BERTI, Francesco; Novartis Vaccines and Diagnostics SrL, Via Fiorentina 1, 1-53100 Siena (IT). ADAMO, Roberto; Novartis Vaccines and Diagnostics SrL, Via Fiorentina 1, 1-53100 Siena (IT). COSTANTINO, Paolo; Novartis Vaccines and Diagnostics SrL, Via Fiorentina 1, 1-53100 Siena (IT). (74) Agents: EVANS, Stephen John Eves et al.; Novartis Vac­ cines and Diagnostics S.r.L, Via Fiorentina 1, 1-53100 Si­ ena (IT). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) CJ m oo •t i> i-H cn i-H o CJ o & (54) Title: MENINGOCOCCUS SEROGROUP X CONJUGATE (57) Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate typically made is by (a) oxidising primary hydroxyl group in a the capsular polysaccharide, give to an oxid­ ised polysaccharide with an aldehyde group; and (b) coupling the oxidised polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms there­ of. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.
SG11201407440WA 2012-05-22 2013-05-22 Meningococcus serogroup x conjugate SG11201407440WA (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US201261650025P true 2012-05-22 2012-05-22
US201261698677P true 2012-09-09 2012-09-09
US201361799528P true 2013-03-15 2013-03-15
PCT/EP2013/060447 WO2013174832A1 (en) 2012-05-22 2013-05-22 Meningococcus serogroup x conjugate

Publications (1)

Publication Number Publication Date
SG11201407440WA true SG11201407440WA (en) 2014-12-30

Family

ID=48470983

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201608675YA SG10201608675YA (en) 2012-05-22 2013-05-22 Meningococcus serogroup x conjugate
SG11201407440WA SG11201407440WA (en) 2012-05-22 2013-05-22 Meningococcus serogroup x conjugate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201608675YA SG10201608675YA (en) 2012-05-22 2013-05-22 Meningococcus serogroup x conjugate

Country Status (13)

Country Link
US (2) US10124051B2 (en)
EP (1) EP2852414A1 (en)
JP (2) JP2015518845A (en)
KR (1) KR20150021933A (en)
CN (1) CN104736180A (en)
AU (1) AU2013265336A1 (en)
BR (1) BR112014029313A2 (en)
CA (1) CA2874210A1 (en)
IL (1) IL235543D0 (en)
MX (1) MX2014014067A (en)
RU (1) RU2014151567A (en)
SG (2) SG10201608675YA (en)
WO (1) WO2013174832A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007016237A (en) 2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Immunogenic composition.
EP2809349B1 (en) * 2012-01-30 2018-12-19 Serum Institute Of India Private Limited Immunogenic composition
SG11201503947YA (en) * 2012-11-21 2015-06-29 Serum Inst India Ltd Production of high yields of bacterial polysaccharides
WO2015158898A2 (en) * 2014-04-17 2015-10-22 Medizinische Hochschule Hannover Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
EP2952586A1 (en) 2014-06-02 2015-12-09 Serum Institute Of India Ltd. Bacterial capsular polysaccharide yield enhancement by addition of defoaming agents
US10365272B2 (en) * 2014-07-25 2019-07-30 Serum Institute Of India Private Limited Highly sensitive immunoassay for rapid quantification of meningococcal capsular polysaccharide antigens

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
JPS5611436B2 (en) 1977-09-30 1981-03-14
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein Immunogenic membrane protein complex, seen for the front up and tell priority over derav as immune stimulant and as vaccine
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa Glycoprotein conjugate to attivita 'trivalent immunogenic
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag Synthetic antigenic, process for their production and their use
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use for the development of synthetic vaccines.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren Protein D - an IgD-binding protein FROM Haemophilus influenzae, and anvaendning this Foer analysis, vaccines and uppreningsaendamaal
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
FR2686798B1 (en) 1992-01-31 1994-03-25 Salomon Sa Device designed to modify the distribution of the ski on its gliding surface and ski equipped with such a device.
IT1262896B (en) 1992-03-06 1996-07-22 Compounds conjugates formed by heat shock proteins (hsp) poly- and oligo-saccharides, their use for the production of vaccines.
JP3755890B2 (en) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) Adjuvanted vaccine composition
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
NZ305365A (en) 1995-04-25 1999-05-28 Smithkline Beecham Biolog A vaccine containing an antigen, an immunologically active saponin and a sterol
ES2164251T5 (en) 1995-06-07 2006-06-01 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide-protein carrier and protein-free antigen conjugated conveyor.
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
EP2172216A3 (en) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
DE69815692T2 (en) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Oil in water emulsions with saponins
BR9814878A (en) 1997-11-21 2000-10-03 Genset Sa genÈmica sequence and polypeptides of Chlamydia pneumoniae, fragments thereof, and uses thereof, particularly for the diagnosis, prevention and treatment of infection
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
EP2218730A1 (en) 1997-11-28 2010-08-18 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
BR9907884A (en) 1998-02-12 2000-10-24 American Cyanamid Co A vaccine composition, methods for generating an immune response in an antigen pneumococcal to increase IFN-gamma response to pneumococcal vaccine, and to generate additional fixing antibodies to a protective response to a pathogen immunogenic composition and method for generating an immune response in a meningococcal antigen
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE69941574D1 (en) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenous beta-propionamido-bonded polysaccharid protein conjugate is suitable for vaccination and manufactured by using n-acryloylated polysaccharide
DE122007000087I1 (en) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvancy systems and vaccines
WO2000027994A2 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
EP1034792A1 (en) 1999-03-11 2000-09-13 Ingileif Jonsdottir Intranasal delivery of pneumococcal polysaccharide vaccines
EP2277535A3 (en) 1999-03-19 2011-03-09 GlaxoSmithKline Biologicals SA Vaccine
FR2791895B1 (en) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Use of trehalose to stabilize a liquid vaccine
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
CN1391483A (en) 1999-09-24 2003-01-15 史密丝克莱恩比彻姆生物有限公司 Composition of octoxinol and polyvinyl chloride sorbitanate as accessory and uses in vaccins
HU0203817A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
EP1311288A1 (en) 2000-01-20 2003-05-21 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
JP2004502415A (en) 2000-07-03 2004-01-29 カイロン エセ.ピー.アー. Immunization against Chlamydiapneumoniae
WO2002026757A2 (en) 2000-09-26 2002-04-04 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
AU1412702A (en) 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
ES2544979T3 (en) 2001-01-23 2015-09-07 Sanofi Pasteur Inc. Polysaccharide conjugate vaccine-CRM197 tri- or tetravalent Meningococcal
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2002330681C1 (en) 2001-07-26 2015-04-02 Glaxosmithkline Biologicals S.A. Vaccines comprising aluminium adjuvants and histidine
JP4516748B2 (en) 2001-09-14 2010-08-04 サイトス バイオテクノロジー アーゲー Packaging immunostimulatory substances in virus-like particles: preparation and use
CA2492823A1 (en) 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
US20040096461A1 (en) 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
GB0217909D0 (en) 2002-08-01 2002-09-11 Du Pont Chintzed stretch fabrics
WO2004018646A2 (en) 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
EP1551357B1 (en) 2002-09-13 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Group b streptococcus vaccine
EP1587473A4 (en) 2002-12-27 2008-08-13 Novartis Vaccines & Diagnostic Thiosemicarbazones as anti-virals and immunopotentiators
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
CN102174534A (en) 2003-04-15 2011-09-07 英特塞尔股份公司 S. pneumoniae antigens
DE602004022286D1 (en) * 2003-06-02 2009-09-10 Novartis Vaccines & Diagnostic Immunogenic compositions based on biodegradable micro particles containing a diphtheria and tetano toxoid
AU2004251742A1 (en) 2003-06-23 2005-01-06 Sanofi Pasteur, Inc. Immunization method against Neisseria meningitidis serogroups A and C
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
US7833803B2 (en) 2004-05-20 2010-11-16 Novartis Ag Analysis of liquid chromatography eluates
US8632801B2 (en) * 2005-12-28 2014-01-21 Alza Corporation Stable therapeutic formulations
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0703369D0 (en) 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
AU2010227220B2 (en) * 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
US20130012471A1 (en) * 2009-08-26 2013-01-10 Rita Gerardy-Schahn Means and methods for producing artificial capsular polysaccharides of neisseria meningitidis
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
JP2013523898A (en) * 2010-04-15 2013-06-17 マリン ポリマー テクノロジーズ,インコーポレーテッド Antibacterial application of poly-N-acetylglucosamine nanofibers
WO2012061400A2 (en) * 2010-11-01 2012-05-10 University Of Maryland, Baltimore Method for reduction of free polysaccharide in polysaccharide-protein vaccines reactions using ion-exchange matrices
TR201909110T4 (en) * 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Saccharide-protein methods for making the glycoconjugate.
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
US20140260023A1 (en) * 2013-03-15 2014-09-18 Allan Henderson Continuous strand hoop reinforcement for concrete foundations

Also Published As

Publication number Publication date
RU2014151567A (en) 2016-07-10
US20150104479A1 (en) 2015-04-16
CN104736180A (en) 2015-06-24
US10124051B2 (en) 2018-11-13
MX2014014067A (en) 2015-02-04
BR112014029313A2 (en) 2017-06-27
IL235543D0 (en) 2015-01-29
EP2852414A1 (en) 2015-04-01
JP2015518845A (en) 2015-07-06
AU2013265336A1 (en) 2014-12-04
CA2874210A1 (en) 2013-11-28
KR20150021933A (en) 2015-03-03
SG10201608675YA (en) 2016-12-29
WO2013174832A1 (en) 2013-11-28
JP2017088622A (en) 2017-05-25
US20190060437A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
SG11201407411SA (en) Compositions and methods for the treatment of metabolic syndrome
SG11201402826YA (en) Substituted nucleosides, nucleotides and analogs thereof
SG11201408324QA (en) Pyridinone and pyridazinone derivatives
SG11201403402VA (en) Compounds
SG11201407906TA (en) Blended rods for use in aerosol-generating articles
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
AU2013204417B2 (en) Oral Product
SG11201408279QA (en) Social sharing of security information in a group
SG11201407912TA (en) Electrically operated aerosol generating system
SG11201408793XA (en) Methods related to real-time cancer diagnostics at endoscopy utilizing fiber-optic raman spectroscopy
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201408045UA (en) MACROCYCLIC INHIBITORS OF <i>FLAVIVIRIDAE</i> VIRUSES
AU2013205102B2 (en) Oral device and method for the use thereof
SG11201407919WA (en) Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
SG11201407914SA (en) Flavoured rods for use in aerosol-generating articles
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201804118VA (en) Compositions comprising bacterial strains
SG11201408094YA (en) Neprilysin inhibitors
SG11201804839WA (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk